Crispr Therapeutics Ag's Revenue in the fiscal year 2025 $ 3.51 millions
Crispr Therapeutics Ag's Revenue in the fiscal year 2024 $ 37.31 millions
Crispr Therapeutics Ag's Revenue in the fiscal year 2023 $ 371.21 millions
Crispr Therapeutics Ag's Revenue in the fiscal year 2022 $ 1.20 millions
Crispr Therapeutics Ag's Revenue in the fiscal year 2021 $ 914.96 millions
CRSP Revenue third quarter 2026 Y/Y Growth Comment
Crispr Therapeutics Ag reported Revenue surge of 1323.48% year on year in the third quarter 2026, to $ 12.67 millions, this is lower than Crispr Therapeutics Ag's recent average Revenue surge of 9223.92%.
Looking into third quarter 2026 results within Biotechnology & Pharmaceuticals industry 39 other companies have achieved higher Revenue growth. While Crispr Therapeutics Ag' s Revenue doubling of 1323.48% ranks overall at the positon no. 2549 in the third quarter 2026.
Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026
Crispr Therapeutics Ag's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
1666566.67 %
46562.67 %
-100 %
(Mar 31 2023)
CRSP's III. Quarter Q/Q Revenue Comment
Crispr Therapeutics Ag achieved in the III. Quarter 2026 below company average Revenue jump of 24.45% quarter on quarter, to $ 12.67 millions.
Although the III. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the III. Quarter surge, eclipses the 0% growth in the III. Quarter a year ago
Within Biotechnology & Pharmaceuticals industry 3 other companies have achieved higher Revenue quarter on quarter growth. While Crispr Therapeutics Ag's Revenue growth quarter on quarter, overall rank is 42.
Crispr Therapeutics Ag achieved in the III. Quarter 2026 below company average Revenue jump of 24.45% quarter on quarter, to $ 12.67 millions.
III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 0% in the III. Quarter a year ago.
Within Biotechnology & Pharmaceuticals industry 3 other companies have achieved higher Revenue quarter on quarter growth. While Crispr Therapeutics Ag's Revenue growth quarter on quarter, overall rank is 42.
Crispr Therapeutics Ag's 12 Months Revenue Growth Year on Year
Crispr Therapeutics Ag showed decline, but improvement compare to trailing twelve month Revenue decrease in Jun 30 2026. If the fiscal year would end in Sep 30 2026, Crispr Therapeutics Ag's annual Revenue rise would be -34.34% year on year to $25 millions.
In the Healthcare sector 527 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3517 to 3722.
Crispr Therapeutics Ag showed decline, but improvement compare to trailing twelve month Revenue decrease in Jun 30 2026. If the fiscal year would end in Sep 30 2026, Crispr Therapeutics Ag's annual Revenue drop would be -34.34% year on year to $25 millions.
In the Healthcare sector 527 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3517 to 3722.
About Crispr Therapeutics Ag Revenue Growth Rates (CRSP), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
2,135.58%